SCHEMBL20745192

SCHEMBL20745192

COCCOCCOCCOc1ccc(Br)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PI4KA P42356 1/20 0.40
PIK3CG P48736 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
MAPT P10636 3/20 0.40
APP P05067 2/20 0.40
SNCA P37840 1/20 0.40
KDM4E B2RXH2 2/20 0.39
GABRA5 P31644 1/20 0.38
ACACB O00763 1/20 0.36
ALDH1A1 P00352 2/20 0.36
GBA1 P04062 1/20 0.36
LSS P48449 1/20 0.36
DGAT1 O75907 1/20 0.35
OPRM1 P35372 2/20 0.34
RECQL P46063 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18229345 1.00 PIK3CD (0.40) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL7138906 1.00 PIK3CD (0.40) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL256028 0.95 PIK3CD (0.43) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL29773832 0.86 KDM4E (0.42) MAPTAPPSNCAKDM4EGABRA5
SCHEMBL1477138 0.85 KDM4E (0.41) MAPTKDM4EACACBALDH1A1RECQL
SCHEMBL9082771 0.84 KDM4E (0.43) MAPTAPPSNCAKDM4EGABRA5
SCHEMBL22534188 0.83 KDM4E (0.40) MAPTAPPSNCAKDM4EGABRA5
SCHEMBL23720319 0.83 APP (0.40) MAPTAPPSNCAKDM4EGABRA5
SCHEMBL14211685 0.83 APP (0.40) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL23720530 0.83 APP (0.40) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313572-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2025-10-09 US disclosed
US-20240228509-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2024-07-11 US disclosed
US-20230399340-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2023-12-14 US disclosed
US-20200239494-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2020-07-30 US disclosed
EP-3668502-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE AbbVie Inc. (US) 2020-06-24 EP disclosed
WO-2019035927-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC. (US) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228509-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 PIK3CD 3622/4885PIK3CA 2780/4885PIK3CB 3533/4885
US-20200239494-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 PIK3CD 3622/4885PIK3CA 2780/4885PIK3CB 3533/4885
US-20250313572-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 PIK3CD 3622/4885PIK3CA 2780/4885PIK3CB 3533/4885
US-20230399340-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 PIK3CD 3622/4885PIK3CA 2780/4885PIK3CB 3533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.